Search results for " hippocampus."

showing 2 items of 42 documents

Effect of Acetaldehyde Intoxication and Withdrawal on NPY Expression: Focus on Endocannabinoidergic System Involvement

2014

Acetaldehyde (ACD), the first alcohol metabolite, plays a pivotal role in the rewarding, motivational and addictive properties of the parental compound. Many studies have investigated the role of ACD in mediating neurochemical and behavioral effects induced by alcohol administration, but very little is known about the modulation of neuropeptide systems following ACD intoxication and withdrawal. Indeed the neuropeptide Y (NPY) system is altered during alcohol withdrawal in key regions for cerebrocortical excitability and neuroplasticity. The primary goal of this research was to investigate the effects of ACD intoxication and withdrawal by recording rat behavior and by measuring neuropeptide …

medicine.medical_specialtylcsh:RC435-571hippocampusnucleus accumbensHippocampusNeuropeptidePhysical dependenceNucleus accumbensendocannabinoidergic systemNeurochemicallcsh:PsychiatryInternal medicinemental disordersmedicineendocannabinoid systemneuropeptide Y expressionOriginal ResearchPsychiatryacetaldehyde withdrawal neuropeptide Y expression endocannabinoidergic system hippocampus nucleus accumbensKindlingAlcohol dependenceacetaldehyde withdrawal neuropeptide Y expression endocannabinoidergic system hippocampusnucleus accumbensNeuropeptide Y receptorPsychiatry and Mental healthEndocrinologyacetaldehyde withdrawalmedicine.symptomPsychologyFrontiers in Psychiatry
researchProduct

CHF2819: Pharmacological profile of a novel acetylcholinesterase inhibitor

2002

CHF2819 is a novel orally active acetylcholinesterase inhibitor (AChEI) developed for the treatment of Alzheimer's disease (AD). CHF2819 is a selective inhibitor of AChE, it is 115 times more potent against this enzyme than against butyrylcholinesterase (BuChE). Moreover, CHF2819 is more selective for inhibition of central (brain) AChE than peripheral (heart) AChE. In vivo CHF2819, 0.5, 1.5, and 4.5 mg/kg p.o., significantly and in dose-dependent manner increased acetylcholine (ACh) levels in hippocampus of young adult rats. Moreover, aging animals, with lower basal ACh levels than young adult rats, also exhibit a marked increase in hippocampal levels of this neurotransmitter after administ…

medicine.medical_specialtymedicine.drug_classPhenylcarbamatesPharmacologyHippocampusArticleCyclic N-Oxideschemistry.chemical_compoundNeurochemicalAlzheimer DiseaseDopamineInternal medicinemedicineAnimalsBiogenic MonoaminesAmino AcidsNeurotransmitterButyrylcholinesteraseCholinesterasePharmacologybiologybusiness.industryGlutamate receptoracetylcholinesterase inhibitors; alzheimer's disease; amino acids; chf2819; ganstigmine; neurotransmitters; rat hippocampusAcetylcholineRatsNeuropsychology and Physiological PsychologyEndocrinologyAcetylcholinesterase inhibitorchemistrybiology.proteinCarbamatesCholinesterase InhibitorsbusinessAcetylcholinemedicine.drug
researchProduct